Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04373044 · ClinicalTrials.gov registry record · Phase 2
Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
A Phase 2 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04373044 is a Phase 2 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 6 participants.
The verdict
NCT04373044, a Phase 2 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This phase II trial studies the effect of baricitinib in combination with antiviral therapy for the treatment of patients with moderate or severe coronavirus disease-2019 (COVID-19). Treatment with antiviral medications such as hydroxychloroquine, lopinavir/ritonavir, and/or remdesivir may act against infection caused by the virus responsible for COVID-19. Baricitinib may reduce lung inflammation. Giving baricitinib in combination with antiviral therapy may reduce the risk of the disease from getting worse and may help prevent the need for being placed on a ventilator should the disease worsen compared to antiviral therapy alone.
Interventions
- DRUG Placebo Administration
- DRUG Baricitinib
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-05-01 |
| Est. Completion | 2021-05-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04373044
The ClinicalTrials.gov registry entry for NCT04373044 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Administration is the first listed.
NCT04373044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04373044 about?
NCT04373044 is a clinical study titled "Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19". This phase II trial studies the effect of baricitinib in combination with antiviral therapy for the treatment of patients with moderate or severe coronavirus disease-2019 (COVID-19). Treatment with antiviral medications such as hydroxychloroquine, lopinavir/ritonavir, and/or remdesivir may act again...
What is the current status of trial NCT04373044?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2020-05-01. Estimated completion is 2021-05-12.
What interventions are being tested in trial NCT04373044?
The interventions under investigation include: Placebo Administration (DRUG), Baricitinib (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT04373044?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.